Aeolus Announces No-Cost Extension and Modification of Barda Contract Fully Valued at $118 Million to Develop Treatment for Lung Acute Radiation Syndrome
15 févr. 2012 10h35 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 15, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS)
Restructure driven by additional items added to base...
Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2012 Financial Results
13 févr. 2012 17h40 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 13, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS)
$2.2 million in revenue
Meeting to request...
Aeolus' AEOL 10150 Protects Lung Tissue From Radiation by Modulating PTEN Levels, Reducing Oxidative Stress and Apoptosis
08 févr. 2012 14h35 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 8, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS)
Data published in the International Journal of Radiation...
Positive Data on AEOL 11207 in Pre-Clinical Epilepsy Model Published in the Journal of Neurobiology of Disease
07 févr. 2012 06h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 7, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a...
Aeolus to Present at the Noble Financial Capital Markets' 8th Annual Equity Conference
17 janv. 2012 06h58 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Jan 17, 2012) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a...
Aeolus Pharmaceuticals Announces Fiscal Year 2011 Results
27 déc. 2011 19h10 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Dec 27, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a...
Aeolus to Present at the 22nd Annual Oppenheimer Healthcare Conference
07 déc. 2011 11h17 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Dec 7, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a...
Aeolus to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
09 nov. 2011 09h05 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Nov 9, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a platform...
Aeolus Pharmaceuticals Announces Positive Results From Study of AEOL 10150 and Neupogen(R) as Combination Therapy for Treatment of Acute Radiation Syndrome
01 nov. 2011 08h00 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Nov 1, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant government funding to develop a...
Aeolus to Present at the 10th Annual BIO Investor Forum
24 oct. 2011 10h02 HE
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Oct 24, 2011) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a biotechnology company leveraging significant funding from the U.S. Department of...